argenx NV ADR Asset Resilience Ratio

Latest as of June 2026: 15.95%

argenx NV ADR asset resilience ratio. argenx NV ADR (ARGX) has an Asset Resilience Ratio of 15.95% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does argenx NV ADR carry for a breakdown of total debt and financial obligations.

Liquid Assets

$1.60 Billion
Cash + Short-term Investments

Total Assets

$10.03 Billion
All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio of argenx NV ADR (2012–2025)

Asset resilience ratio of argenx NV ADR from 2012 to 2025. This chart shows how argenx NV ADR's Asset Resilience Ratio has changed over time. See how much free cash does argenx NV ADR generate to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down argenx NV ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ARGX total asset value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $1.60 Billion 15.95%
Total Liquid Assets $1.60 Billion 15.95%

Asset Resilience Insights

  • Good Liquidity Position: argenx NV ADR maintains a healthy 15.95% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

argenx NV ADR Industry Peers by Asset Resilience Ratio

Compare argenx NV ADR's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
HLB Co. Ltd
KQ:028300
Biotechnology 3.29%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Shanghai Medicilon Inc
SHG:688202
Biotechnology 6.69%
Blue Jet Healthcare Limited
NSE:BLUEJET
Biotechnology 13.81%
Hangzhou Biotest Biotech Co Ltd
SHG:688767
Biotechnology 0.56%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 79.76%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%

argenx NV ADR Asset Resilience Ratio by Year (2012–2025)

argenx NV ADR asset resilience ratio by year from 2012 to 2025. The table below shows the annual Asset Resilience Ratio data for argenx NV ADR.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 10.93% $948.75 Million $8.68 Billion -19.37pp
2024-12-31 30.29% $1.88 Billion $6.20 Billion +5.39pp
2023-12-31 24.90% $1.13 Billion $4.54 Billion -19.51pp
2022-12-31 44.41% $1.39 Billion $3.13 Billion +9.25pp
2021-12-31 35.16% $1.00 Billion $2.85 Billion +0.95pp
2020-12-31 34.20% $779.65 Million $2.28 Billion -35.88pp
2019-12-31 70.08% $1.13 Billion $1.61 Billion +21.07pp
2018-12-31 49.01% $324.33 Million $661.70 Million +3.48pp
2017-12-31 45.54% $202.64 Million $444.98 Million +39.08pp
2016-12-31 6.46% $7.18 Million $111.24 Million -7.10pp
2015-12-31 13.56% $6.81 Million $50.25 Million -35.89pp
2014-12-31 49.45% $28.93 Million $58.51 Million +47.45pp
2013-12-31 2.00% $690.44K $34.54 Million -4.06pp
2012-12-31 6.06% $1.39 Million $22.93 Million --
pp = percentage points

About argenx NV ADR

NASDAQ:ARGX USA Biotechnology
Market Cap
$48.76 Billion
Market Cap Rank
#583 Global
#283 in USA
Share Price
$787.95
Change (1 day)
-0.66%
52-Week Range
$532.27 - $929.61
All Time High
$929.61
About

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more